

June 2004

# Update Information



## NEW DRUG TERMS

	<u>NUMBER</u>
20K-HGH .....	68280026
A-6 .....	14000105
CCI-779 .....	10120807
DASB .....	95000290
ELDERBERRY .....	92510183
EM-800 .....	10100008
ESZOPICLONE .....	28240829
IVL-745 .....	92000267
M-100240 .....	44100091
UROTENSIN II .....	14000104
UZARA .....	92510182

## CONTINUING EDUCATION ARTICLES

**Article Number 516181:** Pleasants RA. Focus on Inhaled Beta2-Agonists: Efficacy, Safety, and Patient Preference. (*IDIS* Note: The 2.0 Hours of CE Credit is for Articles 516180 and 516181). *Pharmacotherapy* 2004, 24:44S-54S. (0.2 CEU)

**Article Number 516180:** MacIntyre NR. Chronic Obstructive Pulmonary Disease. (*IDIS* Note: The 2.0 Hours of CE Credit is for Articles 516180 and 516181). *Pharmacotherapy* 2004, 24:33S-43S. (0.2 CEU)

**Article Number 516006:** Nice FJ, Deeugenio D, Dimino TA, Freeny IC, et al. Medications and Breast-Feeding: A Guide for Pharmacists, Pharmacy Technicians, and Other Healthcare Professionals Part III. *J Pharm Technology* 2004, 20:165-177. (0.1 CEU)

**Article Number 515956:** Long CL, Raebel MA, Price DW, Magid DJ. Compliance with Dosing Guidelines in Patients with Chronic Kidney Disease. *Ann Pharmacotherapy* 2004, 38:853-858. (0.1 CEU)

**Article Number 515954:** Anthony KK, Mauro VF. Rate Versus Rhythm Control in Atrial Fibrillation. *Ann Pharmacotherapy* 2004, 38:839-844. (0.1 CEU)

**Article Number 515688:** Cada DJ, Levien T, Baker DE. Rosuvastatin Calcium. *Hosp Pharm* 2004, 39:52-68. (0.15 CEU)

**Article Number 515642:** Cada DJ, Levien T, Baker DE. Daptomycin. *Hosp Pharm* 2004, 39:161-171. (0.15 CEU)

**Article Number 515359:** Cada DJ, Levien T, Baker DE. Risperidone Long-Acting Injection. *Hosp Pharm* 2004, 39:353-363. (0.15 CEU)

### **FDA APPROVAL PACKAGE**

**Article Number 514820-514830:** Anonymous. Annotated Table of Contents. **Cetrorelix Acetate for Injection, Cetrotide.** Summary Basis of Approval Equivalent. *FDA Approval Package* 2000.

(continued)

## SUBSCRIBER NOTES

**2004 CD-ROM (1985-current) disc return procedures:** It is not necessary to return your monthly outdated (1985-current) Index Record disc to *IDIS*. After you have checked your new monthly (1985-current) Index Record disc, please destroy the previous month's disc. The Article disc is a permanent file, **NEVER DISCARD!** Place the disc at the end of your current article disc file in chronological order for easy access.

***IDIS* WWW Home Page:** Iowa Drug Information Service has a Home Page on the WWW linked to the University of Iowa. Copies of the *World of Drug Information* newsletter, FDA Approval Packages and a form to request a CD-ROM or Web trial can be found here. You can also send us an Internet message directly from our Home Page. The address is: <http://www.uiowa.edu/~idis>

***IDIS* toll-free number:** A toll-free number is available to our U.S. subscribers for questions, comments or inquiries. The number is 1-800-525-4347 (1-800-525-*IDIS*). We encourage you to make use of this number.

**Retrieval Software Sublicense Agreement (RSSA):** It is not necessary for CD-ROM subscribers to sign an RSSA agreement for their 2004 *IDIS* subscription. A copy of the RSSA will be enclosed with each monthly update shipment.

**CD-ROM Retrospective Articles:** The 1997 - 2003 CD-ROM articles are available for purchase. Please check your 2004 Price Sheet for cost information.

## NEW DRUG BIBLIOGRAPHIES

Cinacalcet

### **Cinacalcet Hydrochloride Tablet, Sensipar®, Amgen**

---

<b>FDA Approval</b>	March 8, 2004, priority review
<b>Indication</b>	Use in the treatment of patients with secondary hyperparathyroidism with chronic kidney disease on dialysis and hypercalcemia associated with parathyroid carcinoma.
<b>IDIS Database</b>	5 Randomized Controlled Clinical Trials 1 Editorial 1 Review 1 Report
<b>IDIS Drug Term</b>	CINACALCET 92000409
<b>IDIS Disease Terms</b>	FAILURE, RENAL 586. HYPERPARATHYROIDISM 252.0 DISORDER, CALCIUM METABOLISM 275.4

Pemetrexed

### **Pemetrexed Injection, Alimta®, Eli Lilly**

---

<b>FDA Approval</b>	February 4, 2004, priority review for previous orphan drug
<b>Indication</b>	Use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma-a rare type of cancer. It is the first drug approved for this condition.
<b>IDIS Database</b>	1 Randomized Controlled Clinical Trial (Phase III) 16 Observational Studies, No Control (Phase II) 9 Observational Studies, No Control (Phase I) 2 Editorials 1 Letter to the Editor 3 Reviews 2 Reports
<b>IDIS Drug Term</b>	PEMETREXED 10081209
<b>IDIS Disease Term</b>	NEOP, MGN-PLEURA 163.